HIV and ID Observations

Just as pitchers and catchers report to Spring Training this week, many HIV specialists are gearing up for the 17th Conference on Retroviruses and Opportunistic Infections (CROI), which starts this Tuesday in San Francisco.

(I don’t suppose many people see the link between those two events.  Oh well.)

And since the “pocket program” to the Conference has been available since last week, below is a highly-subjective (admittedly developed-world centric) list of potentially important presentations, in a somewhat random order.  Apologies ahead of time for leaving off something of great importance, most likely buried somewhere deep in the poster presentations.

• 28 Immunodeficiency, HIV RNA Levels, and Risk of Non-AIDS-defining Cancers
• 30 HIV Infection Is an Independent Risk Factor for Lung Cancer
• 33 Decreases in Community Viral Load Are Associated with a Reduction in New HIV Diagnoses in San Francisco
• 34 Monitoring the Impact of Expanded HIV Testing in the District of Columbia Using Population-based HIV/AIDS Surveillance Data
• 53 Safety and Efficacy of TBR 652, a CCR5 Antagonist, in HIV-1-infected, ART-experienced, CCR5 Antagonist–Naïve Patients
• 54LB Phase 3 Trials of Vicriviroc in Treatment-experienced Subjects Demonstrate Safety but Not Significantly Superior Efficacy over Potent Background Regimens Alone
• 57 Efficacy and Safety at 48 Weeks of Once-daily vs Twice-daily DRV/r in Treatment-experienced HIV-1+ Patients with No DRV Resistance-associated Mutations: The ODIN Trial
• 58LB Single-tablet, Fixed-dose Regimen of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Achieves a High Rate of Virologic Suppression and GS-9350 Is an Effective Booster
• 59LB ACTG 5202: Final Results of ABC/3TC or TDF/FTC with either EFV or ATV/r in Treatment-naïve HIVinfected Patients*
• 74 RV 144 Update: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thai Adults
• 87LB PRO2000 Vaginal Gel is Ineffective in Preventing HIV Infection: Results of the MDP301 Phase III Microbicide Trial
• 88LB Association of Expanded HAART Coverage with a Decrease in New HIV Diagnoses, Particularly among Injection Drug Users in British Columbia, Canada
• 101LB Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response
• 106LB Bone and Limb Fat Outcomes of ACTG A5224s, a Substudy of ACTG A5202: A Prospective, Randomized, Partially Blinded Phase III Trial of ABC/3TC or TDF/FTC with EFV or ATV/r for Initial Treatment of HIV-1 Infection*
• 107LB Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: TheEuroSIDA Study
• 125 Rapid Progression of Atherosclerosis at the Carotid Bifurcation Is Linked to Inflammation in HIV-infected Patients
• 128 Higher and Increasing Rates of Fracture among HIV-infected Persons in the HIV Outpatient Study Compared to the General US Population, 1994 to 2008
• 129 HIV Infection and Fragility Fracture Risk among Male Veterans
• 134 A Finite Course of ART during Early HIV-1 Infection Modestly Delays Need for Subsequent ART Initiation:ACTG A5217, the SETPOINT Study
• 135LB Profound Depletion of HIV-1 Transcriptionally Active PBMC by Early cART during Primary HIV-1 Infection but Not by Treatment during Chronic Infection: Results of the Zurich Primary HIV Infection Study
• 136 ART and Risk of Heterosexual HIV-1 Transmission in HIV-1 Serodiscordant African Couples: A Multinational Prospective Study
• 153LB Efficacy of ART with NVP+TDF/FTC vs LPV/r+TDF/FTC among Antiretroviral-naïve Women in Africa: OCTANE Trial 2/ACTG A5208
• 263  Longer Phase I Viral Decay in Treatment-naïve Patients Receiving Raltegravir-based ART: Preliminary Results from ACTG 5248
• 285 Maraviroc Intensification for Suboptimal CD4+ Cell ResponseDespite Sustained Virologic Suppression: ACTG 5256
• 476 Strong Effect of Early ART during Primary HIV-1 Infection in Preventing further Spread of HIV in Sexually Active Men Having Sex with Men
• 510 A One-pill, Once-daily Fixed-dose Combination of Efavirenz, Emcitrabine, and Tenofovir Disoproxil Fumarate Regimen Is Associated with Higher Unannounced Pill Count Adherence than Non-one-pill, Once-daily Regimens
• 526 Life Expectancy of Recently Diagnosed Asymptomatic HIV-infected Patients Approaches that of Uninfected Individuals
• 527 Time with CD4 Cell Count above 500 cells/mm3 Allows HIV-infected Men, but Not Women, to Reach Similar Mortality Rates to Those of the General Population: A 7-year Analysis
• 983 CD4 at HAART Initiation Predicts Long-term CD4 Responses and Mortality from AIDS and Non-AIDS Causes in the HIV Outpatient Study
• 503 Episodes of HIV Viremia and the Risk of Non-AIDS Events among Successfully Treated Patients
• 504 Persistent Low-level Viremia Is Associated with Increased Risk of Virologic Failure and Mortality
• 505 Association between Low-level Viremia below 50 Copies/mL and Risk of Virologic Rebound in HIV-infected Patients Receiving HAART
• 508 Relative Effectiveness of Preferred Initial Antiretroviral Regimens in the CFAR Network of Integrated Clinical Systems Cohort
• 509 Early ART Compared to Deferred ART during Acute Opportunistic Infection Leads to a Reduction in the Systemic Inflammatory Response Resulting in Improved Immunologic Outcomes
• 707 Earlier Initiation of ART in HIV-infected Individuals Is Associated with Reduced Arterial Stiffness
• 708 Inflammation Is Associated with Endothelial Dysfunction among Individuals with Treated and Suppressed HIV Infection
• 714 Incomplete Immune Recovery on HAART Is Associated with Significantly More Cardiovascular Events and a Trend Towards More Non-AIDS-related Malignancies in Dutch ATHENA Cohort
• 716 Abacavir Induces Human Leukocyte Endothelial Cell Interactions
• 717 Abacavir, a Competitive Inhibitor of Soluble Guanylyl Cyclase, Increases Platelet Reactivity
• 718 Changes in Cardiovascular Biomarkers with Abacavir: A Randomized, 96-week Trial
• 720 Metabolic Profiles and Body Composition Changes in Treatment-naïve HIV-infected Patients Treated with Raltegravir 400 mg Twice-daily vs Efavirenz 600 mg Each Bedtime Combination Therapy: 96-week Follow-up
• 427 Does cART with Greater CNS Penetration Prevent the Development of CNS Opportunistic Diseases?
• 429 Higher CD4 Nadir Is Associated with Reduced Rates of HIV-associated Neurocognitive Disorders in the CHARTER Study: Potential Implications for Early Treatment Initiation
• 734 Low CD4 Cell Count and Impaired Renal Function Are Independent Risk Factors for ARF in HIV-infected Patients
• 735 HAART Is Associated with Improved Kidney Function in Patients with Impaired Kidney Function at Baseline but Was Associated with Slight Worsening of Kidney Function in Patients with Normal Baseline Kidney Function
• 723 A 48-week Randomized Study of Uridine Supplementation vs Switch to TDF on Limb Fat, Mitochondrial Function, Inflammation, and Bone Mineral Density in HIV Lipoatrophy
• 725 Inflammation and Mortality in HIV-infected Adults: Analysis of the FRAM Study Cohort
• 740 Predictors for Change in Estimated Glomerular Filtration Rate in HIV-infected Individuals with or without cART: The Swiss HIV Cohort Study
• 742 Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovircontaining Regimens
• 746 Longitudinal Analysis of Bone Mineral Density in Aging Men with or at Risk for HIV Infection
• 748 Bone Turnover, and in Particular Osteoclast Activity, Is Increased in Patients with Confirmed Proximal Renal Tubulopathy within the Swiss HIV Cohort Study
• 750 Assessment of Vitamin D Levels among HIV-infected Personsin the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy: SUN Study
• 752 High Prevalence of Severe Vitamin D Deficiency in cARTnaïve and Successfully Treated Swiss HIV Patients
• 554 Resistance-associated Mutations to Integrase Inhibitor S/GSK1349572 in HIV-1 Integrase Inhibitor-naïve and Raltegravir-experienced Patients
• 580 Prevalence of Transmitted Antiretroviral Drug Resistance among Newly-diagnosed HIV-1-infected Persons, US, 2007
• 581 Prevalence of Mutations Associated with Transmitted Drug Resistant HIV among BED Recent Versus Long-term Infections, US, 2006
• 585 Decreasing Prevalence of Drug Resistance Mutations over a 7 Year Period in the CFAR Network of Integrated Clinical Systems
• 594 Early Switch Based on Virological Failure Reduces Complexity of HIV-1 Drug Resistance

(*Disclosure:  I’m a co-author on these presentations.)